Kinimmune Wins Highly Competitive Nci Funding To Advance Solid Tumor Immunotherapy For Patients Refractory To Checkpoint Inhibitors
Round Type
Funding Round
St. LouisBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Kinimmune, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced that the company has received $400k in funding from the National Cancer Institute (NCI) at the National Institutes of Health for its Phase I STTR application, “Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers”. This award will advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn ‘cold’ tumors ‘hot’ for synergy with immuno-oncology drugs such as checkpoint inhibitors.
Quick answer
Kinimmune raised an undisclosed amount in a Funding Round round, dated November 9, 2022. Kinimmune is based in St. Louis, Missouri, United States.
- How much did Kinimmune raise?
- Kinimmune raised an undisclosed amount in a Funding Round round on November 9, 2022.
- What does Kinimmune do?
- Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors.
- Where is Kinimmune based and how big is it?
- Kinimmune is based in St. Louis, Missouri, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Kinimmune that raised within 45 days of this round, from Fundz verified event records.
- GenSight Biologics raised $13M (Convertible Note) on December 23, 2022.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- Alpha-9 Theranostics raised $75M (Series B) on December 14, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Opna Bio raised $38M (Series A) on November 21, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
Who to call at Kinimmune, and when
A new round usually means Kinimmune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kinimmune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kinimmune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kinimmune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kinimmune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Kinimmune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.